All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Xenova Group plc immediately expects to commence the first of two planned Phase III trials for TransMID, a candidate for brain cancer. (BioWorld Today)